ls LK. Therapeutic considerations for malignant carcinoid syndr
ome. Acta Oncol，1989；28(3)：433
　8　Yinik A, Binder M, Choil TK, et al. Treatment of the carcinoid syn
drome with the somatostatin analogue. Dig Dis Sci，1989；34(1)：14
　9　Joensum H, Burroughs AK. Dramatic response of a metastatic careimo
id tumor to a comibnation of interferon and octreotide. Acta Endocrinol
Copenh，1992；126：184
　10　Glaser B, Rosler A, Halperin Y. Chronic treatment of a benign ins
ulinoma using the longacting somatostatin analogue SMS 201-955. Isr J M
ed Sci，1990；26(1)：16
　11　Verschoor L, Uitterlinden P, Lamberts SW, et al. On the use of a
new somatostatin analogue in the treatment of hypoglycaemia in patients
with insulinoma. Chin Endocrinool，1986；25(5)：555
　12　Vance ML. Long-term treatment of 18 acromegalic patients with the
somatostatin analog octreotide. Arch Intern Med，1991；151：1573
　13　Eijeck CHJ. Somatostatin receptor-dependent growth inhibition of
liver metastases by octreotide. Br J Surg，1994；81(9)：1333
　14　Maton PN, Kussin P. The use of the long-acting somatostatin analo
gue, octreotide acetate. in patients with islet cell tumors. Gastroente
rol Clin North Am，1989；18：897
　15　Lorcy Y, Derennes V, Delanbre C, et al. Remission of recurrent Cu
shing’s disease with an analog of somatostatin(letter). Presse Med，19
8
8；17：1217
　16　Zhu X F, Melmed S, Torres AJ, et al. Effect of small doses of som
atostatin analog. octreotide, on gallbladder contractility in normal ch
inese adults. Dig Dis Sci，1992；37(1)：105